Cruz A, Bühling M, Seibel K
Arzneimittelforschung. 1985;35(7):1086-9.
In a double-blind trial of 3 months 24 hypotensive patients suffering from migraine were treated with etilefrine pivalate (K 30 052, Ep, 20 mg p.o.) or dihydroergotamine (DHE, 5 mg) or placebo. The number of attacks of migraine was significantly reduced after the 3-month treatment with Ep resp. DHE comparing with placebo. Duration of attacks, intensity and number of additional analgetic drugs were also clearly reduced after medication of Ep and DHE - in contrast to placebo medication. Effectiveness and tolerance of Ep were estimated well and occurring side-effects were only of short duration. Thus the antihypotonics Ep and DHE offer an effective therapeutic scheme for migraine in hypotensive patients. This is in accordance with the fact that hypotension plays an important role in the occurrence of migraine.
在一项为期3个月的双盲试验中，24名患有偏头痛的高血压患者接受了匹伐依替福林（K 30 052，Ep，口服20毫克）、双氢麦角胺（DHE，5毫克）或安慰剂治疗。与安慰剂相比，使用Ep或DHE进行3个月治疗后，偏头痛发作次数显著减少。使用Ep和DHE治疗后，发作持续时间、强度以及额外止痛药物的使用次数也明显减少，这与使用安慰剂治疗形成对比。Ep的有效性和耐受性评估良好，出现的副作用仅持续较短时间。因此，抗高血压药物Ep和DHE为高血压患者的偏头痛提供了一种有效的治疗方案。这与低血压在偏头痛发作中起重要作用这一事实相符。
